Perioperative infusion of low- dose of vasopressin for prevention and management of vasodilatory vasoplegic syndrome in patients undergoing coronary artery bypass grafting-A double-blind randomized study

Journal of Cardiothoracic Surgery

Volumn 5, Issue 1, 2010, Pages

  Papadopoulos, Georgios ^a   Sintou, Eleni ^a   Siminelakis, Stavros ^a   Koletsis, Efstratios ^b   Baikoussis, Nikolaos G ^b   Apostolakis, Efstratios ^b  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

VASOPRESSIN DERIVATIVE;

ADULT; AGED; ARTICLE; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEMODYNAMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; MORTALITY; PEROPERATIVE CARE; POSTOPERATIVE CARE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VASOPLEGIA;

ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; FEMALE; HEMODYNAMICS; HUMANS; INFUSIONS, INTRAVENOUS; INTRAOPERATIVE CARE; MALE; MIDDLE AGED; POSTOPERATIVE CARE; TREATMENT OUTCOME; VASOPLEGIA; VASOPRESSINS;

EID: 77952296050     PISSN: None     EISSN: 17498090     Source Type: Journal    
DOI: 10.1186/1749-8090-5-17     Document Type: Article

References (42)

1. Carrel T, Englberger L, Mohacsi P, Neidhart P, Schmidli J. Low systemic vascular resistance after cardiopulmonary bypass: incidence, etiology, and clinical importance. J Card Surg 2000, 15:347-353. 10.1111/j.1540-8191.2000.tb00470.x, 11599828.
2. Sun X, Zhang L, Hill PC, Lowery R, Lee AT, Molyneaux RE, Corso PJ, Boyce SW. Is incidence of postoperative vasoplegic syndrome different between off-pump and on-pump coronary artery bypass grafting surgery?. Eur J Cardiothorac Surg 2008, 34:820-825. 10.1016/j.ejcts.2008.07.012, 18715792.
3. Noto A, Lentini S, Versaci A, Giardina M, Risitano DC, Messina R, David A. A retrospective analysis of terlipressin in bolus for the management of refractory vasoplegic hypotension after cardiac surgery. Interact CardioVascular and Thoracic Surgery 2009, 9:588-92.
4. Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology 2002, 97:215-52. 10.1097/00000542-200207000-00030, 12131125.
5. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001, 345:588-595. 10.1056/NEJMra002709, 11529214.
6. Wenzel V, Krismer AC, Arntz HR, Sitter H, Stadlbauer KH, Lindner KH. A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N Engl J Med 2004, 350:105-113. 10.1056/NEJMoa025431, 14711909.
7. Gomes WJ, Carvalho AC, Palma JH, Goncalves I, Buffolo E. Vasoplegic syndrome: a new dilemma. J Thorac Cardiovasc Surg 1994, 107:942-3.
8. Gomes WJ, Carvalho AC, Palma JH, Teles CA, Branco JN, Silas MG, Buffolo E. Vasoplegic syndrome after open heart surgery. J Cardiovasc Surg (Torino) 1998, 39:619-23.
9. Levin RL, Degrange MA, Bruno GF, Del Mazo CD, Taborda DJ, Griotti JJ, Boullon FJ. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 2004, 77:496-9. 10.1016/S0003-4975(03)01510-8, 14759425.
10. Shanmugam G. Vasoplegic syndrome-the role of methylene blue. Eur J Cardio-thoracic Surg 2005, 28:705-10.
11. Argenziano M, Chen J, Choundhri A, Cullinane S, Garfein E, Weinberg AD, Smith CR, Rose EA, Landry DW, Oz MC. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 1998, 116:973-80. 10.1016/S0022-5223(98)70049-2, 9832689.
12. Luckner G, Duenser M, Jochberger S, Mayr VD, Wenzel V, Ulmer H, Schmid S, Knotzer H, Pajk W, Hasibeder W, Mayr AJ, Friesenecker B. Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 2005, 33:2659-2666. 10.1097/01.CCM.0000186749.34028.40, 16276194.
13. Duenser MW, Wenzel V, Mayr AJ, Hasibeder WR. Management of vasodilatory shock: Defining the role of arginine vasopressin. Drugs 2003, 63:237-256. 10.2165/00003495-200363030-00001, 12534330.
14. Duenser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR. Arginine vasopressin in advanced vasodilatory shock: A prospective, randomized, controlled study. Circulation 2003, 107:2313-2319. 10.1161/01.CIR.0000066692.71008.BB, 12732600.
15. Morales D, Garrido M, Madigan J, Helman D, Faber J, Williams M, Landry D, Oz M. A double-blind randomized trial: Prophylactic Vasopressin Reduces Hypotension After Cardiopulmonary Bypass. Ann Thorac Surg 2003, 75:926-30. 10.1016/S0003-4975(02)04408-9, 12645718.
16. Morales D, Gregg D, Helman D, Williams MR, Naka Y, Landry DW, Oz MC. Arginine vasopressin in the treatment of fifty patients with postcardiotomy vasodilatory shock. Ann Thorac Surg 2000, 69:102-6. 10.1016/S0003-4975(99)01197-2, 10654495.
17. Raja S, Dreyfus G. Vasoplegic syndrome after Off-pump coronary artery bypass surgery. Tex Heart Inst J 2004, 31:421-24. 548246, 15745296.
18. Mekontso-Dessap A, Houel R, Soustelle C, Kirsch M, Thebert D, Loisance DY. Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Ann Thorac Surg 2001, 71:1428-32. 10.1016/S0003-4975(01)02486-9, 11383777.
19. Tuman KJ, McCarthy RJ, O'Connor CJ, Holm WE, Ivankovich AD. Angiotensin-converting enzyme inhibitors increase vasoconstrictor requirements after cardiopulmonary bypass. Anesth Analg 1995, 80:473-9. 10.1097/00000539-199503000-00007, 7864410.
20. Mets B, Michler RE, Delphin ED, Oz MC, Landry DW. Refractory vasodilation after cardiopulmonary bypass for heart transplantation in recipients on combined amiodarone and angiotensin-converting enzyme inhibitor therapy: a role for vasopressin administration. J Cardiothorac Vasc Anesth 1998, 12:326-9. 10.1016/S1053-0770(98)90017-9, 9636919.
21. Argengiano M, Choudhri A, Oz M, Rose E, Smith C, Landry D. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997, 96:286-290.
22. Carrel T, Englberger L, Mohacsi P, Neidhart P, Schmidli J. Low systemic vascular resistance after cardiopulmonary bypass: incidence, etiology, and clinical importance. J Card Surg 2000, 15:347-53. 10.1111/j.1540-8191.2000.tb00470.x, 11599828.
23. Patel B, Chittock D, Russell J, Walley K. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002, 96:576-82. 10.1097/00000542-200203000-00011, 11873030.
24. Suojaranta-Ylinen R, Vento R, Patila T, Kukkonen S. Vasopressin, when added to norepinephrine, was not associated with increased predicted mortality after cardiac surgery. Scand J Surg 2007, 96:314-18.
25. Morales DL, Landry DW, Oz MC. Therapy for vasodilatory shock: Arginine vasopressin. Semin Anesth Periop Med 2000, 19:98-107.
26. Masetti P, Murphy SF, Kouchoukos NT. Vasopressin therapy for vasoplegic syndrome following cardiopulmonary bypass. J Card Surg 2002, 17:485-9. 10.1046/j.1540-8191.2002.01002.x, 12643457.
27. Malay MB, Ashton RC, Landry DW, Townsend RN. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999, 47:699-705. 10.1097/00005373-199910000-00014, 10528604.
28. Albright T, Zimmerman M, Selzman C. Vasopressin in the cardiac surgery intensive care unit. Am J Crit Care 2002, 11:326-332.
29. Mutlu G, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med 2004, 30:1276-91.
30. Torqersen C, Duenser M, Wenzel V, Jochberger S, Mayr V, Schmittinger CA, Lorenz I, Schmid S, Westphal M, Grander W, Luckner G. Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial. Intensive Care Med 2009, 36:57-65. 10.1007/s00134-009-1630-1, 19756505.
31. Argenziano M, Chen JM, Cullinane S, Choudhri AF, Rose EA, Smith CR, Edwards NM, Landry DW, Oz MC. Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation. J Heart Lung Transplant 1999, 18:814-817. 10.1016/S1053-2498(99)00038-8, 10512533.
32. Tayama E, Ueda T, Shojima T, Akasu K, Oda T, Fukunaga S, Akashi H, Aoyagi S. Arginine vasopressin is an ideal drug after cardiac surgery for the management of low systemic vascular resistant hypotension concomitant with pulmonary hypertension. Interact CardioVasc Thorac Surg 2007, 6:715-719. 10.1510/icvts.2007.159624, 17704123.
33. Leone M, Albanese J, Delmas A, Chaabane W, Garnier F, Martin C. Terlipressin in catecholamine-resistant septic shock patients. SHOCK 2004, 22:314-319. 10.1097/01.shk.0000136097.42048.bd, 15377885.
34. Novella S, Martínez C, Pagán R, Hernández R, García-Sacristán A, González-Pinto A, González-Santos J, Benedito S. Plasma levels and vascular effects of vasopressin in patients undergoing coronary artery bypass grafting. Eur J Cardiothorac Surg 2007, 32:69-76. 10.1016/j.ejcts.2007.03.047, 17507236.
35. Delmas A, Leone M, Rousseau S, Albanese J, Martin C. Clinical review: Vasopressin and terlipressin in septic shock patients. Critical Care 2005, 9:212-222. 10.1186/cc2945, 1175907, 15774080.
36. Wenzel V, Lindner K. Employing vasopressin during cardiopulmonary resuscitation and vasodilatory shock as a lifesaving vasopressor. Cardiovascular Research 2001, 51:529-541. 10.1016/S0008-6363(01)00262-0, 11476743.
37. Wenzel V, Lindner K, Prengel A, Maier C, Voelckel W, Lurie KG, Strohmenger HU. Vasopressin improves vital organ blood flow after prolonged cardiac arrest with postcounter-shock pulseless activity in pigs. Crit Care Med 1999, 27:486-92. 10.1097/00003246-199903000-00022, 10199526.
38. Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: A case series. Intensive Care Med 2001, 27:1416-21. 10.1007/s001340101014, 11511958.
39. Bragadottir G, Redfors B, Nygren A, Sellgren J, Ricksten SE. Low-dose vasopressin increases glomerular filtration rate, but impairs renal oxygenation in post-cardiac surgery patients. Acta Anesthesiol Scand 2009, 53:1052-59.
40. Duenser MW, Fries DR, Schobersberger W, Ulmer H, Wenzel V, Friesenecker B, Hasibeder WR, Mayr AJ. Does arginine vasopressin influence the coagulation system in advanced vasodilatory shock with severe multiorgan dysfunction syndrome?. Anesth Analg 2004, 99:201-206. 10.1213/01.ANE.0000118105.85933.8A, 15281530.
41. Treschan T, Peters J. The vasopressin system: Physiology and clinical strategies. Anesthesiology 2006, 105:599-612. 10.1097/00000542-200609000-00026, 16931995.
42. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first twenty years. Haemophilia 2000, 6:60-7. 10.1046/j.1365-2516.2000.00059.x, 10982270.